A RANDOMIZED, DOUBLE-BLIND, EVENT-DRIVEN, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF ORAL RIVAROXABAN WITH PLACEBO FOR REDUCING THE RISK OF DEATH, MYOCARDIAL INFARCTION OR STROKE IN SUBJECTS WITH CHRONIC HEART FAILURE AND SIGNIFICANT CORONARY ARTERY DISEASE FOLLOWING A HOSPITALIZATION FOR EXACERBATION OF HEART FAILURE.

Registry ID

RIVAROXHFA3001 (IMPACT 16302)

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

JANSSEN INC

Start date

2015-05-01

Completion date

2018-05-29

Last update

2014-01-21

Conditions

• CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE
• STROKE
• MYOCARDIAL INFARCTION
• CHRONIC HEART FAILURE

Related clinical trials

• Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
• Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study
• EVALUATION OF AN ASPIRIN-FREE STRATEGY WITH TICAGRELOR IN PATIENTS WITH A MYOCARDIAL INFARCTION TREATED MEDICALLY ALONE (PANTHEON)
• EASI-HF REDUCED - A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND EMPAGLIFLOZIN IN PARTICIPANTS WITH SYMPTOMATIC CHRONIC HEART FAILURE (HF: NYHA II-IV) AND LEFT VENTRICULAR EJECTION FRACTION (LVEF) < 40%
• A PHASE III, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT, COMPARATIVE TRIAL OF FERRIC DERISOMALTOSE VERSUS NO INTRAVENOUS IRON IN IRON-DEFICIENT SUBJECTS WITH SYMPTOMATIC CHRONIC HEART FAILURE
• A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF JK07 IN ADULTS WITH CHRONIC HEART FAILURE (RENEU-HF)

View on source registry